CA2494105A1 - Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease - Google Patents
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease Download PDFInfo
- Publication number
- CA2494105A1 CA2494105A1 CA002494105A CA2494105A CA2494105A1 CA 2494105 A1 CA2494105 A1 CA 2494105A1 CA 002494105 A CA002494105 A CA 002494105A CA 2494105 A CA2494105 A CA 2494105A CA 2494105 A1 CA2494105 A1 CA 2494105A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- carbocycle
- compound
- aryl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
Abstract
Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
Claims (119)
- R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkyl);
R9 is selected from -H and -C1-C8 alkyl;
R10 is selected from Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
R13 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and -C1-8 alkyl-(C3-C8 heterocycle); and Each R14 is independently -H or -C1-C8 alkyl. - 2. The compound of claim 1 wherein w is an integer ranging from 2 to 12.
- 3. A compound of the formula Ib:
or a pharmaceutically acceptable salt or solvate thereof wherein, L- is a Ligand unit;
-A- is a Stretcher unit;
a is 0 or 1;
each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2;
p ranges from 1 to about 20; and -D is a Drug unit of the formula wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkyl);
R9 is selected from -H and -C1-C8 alkyl;
when R1 is -C1-C8 alkyl, -C3-C8 carbocycle, or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached, R10 is selected from when R1 is -H, R10 is selected from:
X is -O-, -S-, -NH- or -N(R14)-, where X is bonded to Y when y is 1 or 2, or X is bonded to W when y is 0;
Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
R13 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R14 is independently independently -H or -C1-C8 alkyl; and R15 is selected from -arylene-, -C3-C8 carbocyclo and -C3-C8 heterocyclo-. - 4. The compound of claim 3 wherein w is an integer ranging from 2 to 12.
- 5. A compound of the formula Ic:
or a pharmaceutically acceptable salt or solvate thereof wherein, L- is a Ligand unit;
-A- is a Stretcher unit;
a is 0 or 1;
each -W- is independently an Amino Acid unit;
w is an integer ranging from 0 to 12;
each n is independently 0 or 1;
p ranges from 1 to about 20; and each -D is independently:
(a) a Drug unit of the formula:
wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkyl);
R9 is selected from -H and -C1-C8 alkyl;
when R1 is -C1-C8 alkyl, -C3-C8 carbocycle, or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached, R10 is selected from when R1 is -H, R10 is selected from:
X is -O-, -S-, -NH- or -N(R14)-, where X is bonded to -C(O)- when y is 1 or 2, or X is bonded to -CH2- when n is 0;
Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
R13 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
Each R14 is independently -H or -C1-C8 alkyl; and R15 is selected from -arylene-, -C3-C8 carbocyclo and -C3-C8 heterocyclo-; or (b) a Drug unit of the formula:
wherein, independently at each location:
R2 is selected from -H and -C1-C8 alkyl;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
R10 is selected from Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
R13 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); and each R14 is independently -H or -C1-C8 alkyl. - 6. The compound of claim 5 wherein w is an integer ranging from 2 to 12.
- 7. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure or a pharmaceutically acceptable salt or solvate thereof, wherein, independently at each location:
R2 is selected from -H and -methyl;
R3 is selected from -H, -methyl, and -isopropyl;
R4 is selected from -H and -methyl; R5 is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R4 and R5 join, have the formula - (CR a R
b)n- where R a and R b are independently selected from -H, -C1-C8 alkyl, and -C3-C8 carbocycle, and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -methyl;
each R8 is independently selected from -OH, -methoxy and -ethoxy;
R10 is selected from R24 is selected from H and -C(O)R25-; wherein R25 is selected from -C1-C8 alkyl, -C3-C8 carbocycle, -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
Z is -O-, -NH-, -OC(O)-, -NHC(O)-, -NR28C(O)- ; where R28 is selected from -H and -C1-C8 alkyl;
n is 0 or 1; and R27 is selected from -H, -N3, -C1-C8 alkyl, -C3-C8 carbocycle, -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) when n is 0; and R27 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) when n is 1. - 8. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure
- 9. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure
- 10. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure
- 11. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure or a pharmaceutically acceptable salt or solvate thereof, wherein, independently at each location:
R1 is selected from -H and -methyl;
R2 is selected from -H and -methyl;
R3 is selected from -H, -methyl, and -isopropyl;
R4 is selected from -H and -methyl; R5 is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R4 and R5 join, have the formula - (CR a R
b)n- where R a and R b are independently selected from -H, -C1-C8 alkyl, and -C3-C8 carbocycle, and N is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -methyl;
each R8 is independently selected from -OH, -methoxy and -ethoxy;
when R1 is -methyl, R10 is selected from where X is -O-, -NH- or -N(R14)- and forms a bond with Y when y is 1 or 2, with W
when y is 0, and with A when w and y are both 0;
Z is -O-, -NH- or -N(R14)-;
R13 is -H or -methyl;
R14 is C1-C8 alkyl; and R15 is -arylene-, -C3-C8 carbocyclo or -C3-C8 heterocyclo-, when R1 is -H, R10 is selected from:
where X is -O-, -NH- or -N(R14)- and forms a bond with Y when y is 1 or 2, with W
when y is 0, and with A when w and y are both 0;
Z is -O-, -NH- or -N(R14)-;
R13 is -H or -methyl;
R14 is C1-C8 alkyl; and R15 is -arylene-, -C3-C8 carbocyclo or -C3-C8 heterocyclo-. - 12. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure
- 13. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure
- 14. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure
- 15. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure
- 16. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure
- 17. A compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where the Ligand unit is an antibody unit.
- 18. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 17 where the antibody unit is a monoclonal antibody unit.
- 19. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 18 where the monoclonal antibody unit is cBR96, cAC10 or 1F6.
- 20. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1 or 3 where -Y.gamma.- is Q is selected from -C1-C8 alkyl, -O-(C1-C8 alkyl), -halogen, -nitro and -cyano; and m is an integer ranging from 0-4, the amino terminus of -.UPSILON..gamma.- forming a bond with a Amino acid unit and the carboxyl terminus of -.UPSILON..gamma.- forming a bond with an Drug unit.
- 21. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -.UPSILON..gamma.- forming a bond with a Ligand unit.
- 22. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.
- 23. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.
- 24. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.
- 25. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.
- 26. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.
- 27. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 21 where -A- is the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.
- 28. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 22 where -A- is the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.
- 29. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 24 where -A- is the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.
- 30. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -W w- is -Phenylalanine-Lysine-, the amino terminus of -W w- forming a bond with a Stretcher unit when a is 1 or with a Ligand unit if a is 0, and the C- terminus of -W w- forming a bond with a Spacer unit when y is 1 or 2, and with a Drug unit when y is 0.
- 31. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -W w- is -valine-citrulline-, the amino terminus of -W w- forming a bond with a Stretcher unit when a is 1 or with a Ligand unit if a is 0, and the C- terminus of -W w- forming a bond with a Spacer unit when y is 1 or 2, and with a Drug unit when y is 0.
- 32. A compound of the formula or a pharmaceutically acceptable salts or solvate thereof wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
X is -O-, -S-, -NH- or -N(R14)-;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
R13 is selected from -H, -OH,-NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R14 is independently -H or -C1-C8 alkyl;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -C1, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -C1, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r-, and -(CH2CH2O)r-CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 33. The compound of claim 32 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 34. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
X is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
R13 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R14 is independently -H or -C1-C8 alkyl;
R15 is selected from -arylene-, -C3-C8 carbocyclo- and -C3-C8 heterocyclo-;
R16 is -Yt-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is wherein G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r-, and -(CH2CH2O)r-CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 35. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
X is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
each R14 is independently -H or -C1-C8 alkyl;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r-, and -(CH2CH2O)r-CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 36. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
X is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
each R14 is independently -H or -C1-C8 alkyl;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r-, and -(CH2CH2O)r-CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 37. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R1 is selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
each R14 is independently -H or -C1-C8 alkyl;
R15 is selected from -arylene-, -C3-C8 carbocyclo- and -C3-C8 heterocyclo-;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r -, and -(CH2CH2O)r- CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 38. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R1 is selected from -C1-C8 alkyl and -C3-C8 carbocycle; and R2 is selected from -H and -C1-C8 alkyl; or R1 and R2 join, have the formula -(CR a R b)n-wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
X is -O-, -S-, -NH- or -N(R14)-;
Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
each R14 is independently -H or -C1-C8 alkyl;
R15 is selected from -arylene-, -C3-C8 carbocyclo- and -C3-C8 heterocyclo-;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -C1, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -C1, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-axylene-, -arylene-C1-C10 alkylene-, -Cl-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)T , and -(CH2CH2O)r-, CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 39. The compound of claim 38 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 40. The compound of claim 38 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 41. The compound of claim 38 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 42. The compound of claim 38 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 43. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R2 is selected from -H and -C1-C8 alkyl;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CR a R b)n- wherein R a and R b are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
Z is -O-, -S-, -NH- or -N(R14)-;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
each R14 is independently -H or -C1-C8 alkyl;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -C1, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -C1, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r- , and -(CH2CH2O)r- CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 44. A compound of the formula or a pharmaceutically acceptable salt or solvate thereof wherein, independently at each location:
R2 is selected from -H and -C1-C8 alkyl;
R3 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
R4 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle) wherein R5 is selected from -H and -methyl; or R4 and R5 join, have the formula -(CRaRb)n- wherein Ra and Rb are independently selected from -H, -C1-C8 alkyl and -C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
R6 is selected from -H and -C1-C8 alkyl;
R7 is selected from -H, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R8 is independently selected from -H, -OH, -C1-C8 alkyl, -C3-C8 carbocycle and -O-(C1-C8 alkoxy);
R9 is selected from -H and -C1-C8 alkyl;
R11 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkyl), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle); or R11 is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;
each R12 is independently selected from -aryl and -C3-C8 heterocycle;
R13 is selected from -H, -OH, -NH2, -NHR14, -N(R14)2, -C1-C8 alkyl, -C3-C8 carbocycle, -O-(C1-C8 alkoxy), -aryl, -C1-C8 alkyl-aryl, -C1-C8 alkyl-(C3-C8 carbocycle), -C3-C8 heterocycle and -C1-C8 alkyl-(C3-C8 heterocycle);
each R14 is independently -H or -C1-C8 alkyl;
R16 is -Yy-Ww-A' wherein each -W- is independently an Amino Acid unit;
-Y- is a Spacer unit;
w is an integer ranging from 0 to 12;
y is 0, 1 or 2; and -A' is selected from wherein G is selected from -C1, -Br, -I, -O-mesyl and -O-tosyl;
J is selected from -C1, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR18;
R17 is selected from -C1-C10 alkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkoxy)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-, -(CH2CH2O)r-, and -(CH2CH2O)r-CH2-;
r is an integer ranging from 1-10; and R18 is -C1-C8 alkyl or -aryl. - 45. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 46. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 47. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 48. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 49. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 50. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 51. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 52. The compound of claim 44 having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 53. The compound of claim 3 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 54. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 55. The compound of claim 3 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 56. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 57. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 58. The compound of claim 3 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 59. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 60. The compound of claim 5 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 61. The compound of claim 3 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 62. The compound of claim 3 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 63. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 64. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 65. The compound of claim 1 having the structure where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.
- 66. The compound of any one of claims 53-65 where p ranges from about 7 to about 9.
- 67. The compound of any one of claims 53-65 where p ranges from about 3 to about 5.
- 68. The compound of any one of claims 53-65 where p ranges from 1 to about 3.
- 69. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44; and a pharmaceutically acceptable carrier or vehicle.
- 70. A method for killing or inhibiting the multiplication of a tumor cell or cancer cell comprising administering to an animal in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.
- 71. A method for treating cancer, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.
- 72. A method for treating an autoimmune disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.
- 73. A method for treating an infectious disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.
- 74. The method of claim 71 further comprising administering to the animal an effective amount of an anticancer agent.
- 75. The method of claim 72 further comprising administering to the animal an effective amount of an immunosuppressant agent.
- 76. The method of claim 73 further comprising administering to the animal an effective amount of an anti-infectious agent.
- 77. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 78. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 79. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 80. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 81. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 82. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 83. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 84. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 3 to about 5.
- 85. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from 1 to about 3.
- 86. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 87. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 88. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 89. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
90. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
91. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
92. The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44, in an isolated or a purified form.
or a pharmaceutically acceptable salt or solvate thereof. - 90. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 91. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof.
- 92. The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44, in an isolated or a purified form.
- 93. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.
- 94. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9
- 95. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.
- 96. The compound of claim 95 wherein L is rituximab.
- 97. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.
- 98. The compound of claim 97 wherein L is S2C6.
- 99. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.
- 100. The compound of claim 99 wherein L is rituximab.
- 101. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.
- 102. The compound of claim 101 wherein L is S2C6.
- 103. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.
- 104. The compound of claim 103 wherein L is rituximab.
- 105. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.
- 106. The compound of claim 105 wherein L is S2C6.
- 107. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.
- 108. The compound of claim 107 wherein L is rituximab.
- 109. A compound having the structure or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.
- 110. The compound of claim 109 wherein L is S2C6.
- 111. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109 and a pharmaceutically acceptable carrier or vehicle.
- 112. A method for killing or inhibiting the multiplication of a tumor cell or cancer cell comprising administering to an animal in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.
- 113. A method for treating cancer, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.
- 114. A method for treating an autoimmune disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.
- 115. A method for treating an infectious disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.
- 116. The method of claim 113 further comprising administering to the animal an effective amount of an anticancer agent.
- 117. The method of claim 114 further comprising administering to the animal an effective amount of an immunosuppressant agent.
- 118. The method of claim 115 further comprising administering to the animal an effective amount of an anti-infectious agent.
- 119. The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109, in an isolated or a purified form.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2802205A CA2802205C (en) | 2002-07-31 | 2003-07-31 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40040302P | 2002-07-31 | 2002-07-31 | |
US60/400,403 | 2002-07-31 | ||
PCT/US2003/024209 WO2004010957A2 (en) | 2002-07-31 | 2003-07-31 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2802205A Division CA2802205C (en) | 2002-07-31 | 2003-07-31 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2494105A1 true CA2494105A1 (en) | 2004-02-05 |
CA2494105C CA2494105C (en) | 2013-04-02 |
Family
ID=31188683
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2802205A Expired - Lifetime CA2802205C (en) | 2002-07-31 | 2003-07-31 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
CA2494105A Expired - Lifetime CA2494105C (en) | 2002-07-31 | 2003-07-31 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2802205A Expired - Lifetime CA2802205C (en) | 2002-07-31 | 2003-07-31 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Country Status (17)
Country | Link |
---|---|
US (5) | US7659241B2 (en) |
EP (3) | EP2353611B1 (en) |
JP (1) | JP4741838B2 (en) |
AT (1) | ATE516818T1 (en) |
AU (2) | AU2003263964C1 (en) |
BE (1) | BE2012C047I2 (en) |
CA (2) | CA2802205C (en) |
CY (2) | CY1111894T1 (en) |
DK (2) | DK2357006T3 (en) |
ES (3) | ES2369542T3 (en) |
FR (1) | FR12C0066I2 (en) |
HK (1) | HK1157180A1 (en) |
HU (2) | HUE027549T2 (en) |
LU (1) | LU92133I2 (en) |
PT (2) | PT1545613E (en) |
SI (2) | SI2357006T1 (en) |
WO (1) | WO2004010957A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11944689B2 (en) | 2016-08-09 | 2024-04-02 | Seagen Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
Families Citing this family (673)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
US7244827B2 (en) | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
DE60234094D1 (en) | 2001-05-11 | 2009-12-03 | Ludwig Inst For Cancer Res Ltd | SPECIFIC TIE PROTEINS AND ITS USE |
US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
PT1545613E (en) | 2002-07-31 | 2011-09-27 | Seattle Genetics Inc | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20040081653A1 (en) * | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
EP2289559B1 (en) | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2004101764A2 (en) | 2003-05-13 | 2004-11-25 | Chiron Corporation | Methods of modulating metastasis and skeletal related events resulting from metastases |
BR122018071808B8 (en) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
US20050175619A1 (en) * | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
AU2005216251B2 (en) * | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7837980B2 (en) * | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
CN101098854B (en) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | Bivalent linkers and conjugates thereof |
CA2583208C (en) * | 2004-10-15 | 2015-08-25 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US8337838B2 (en) * | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
DK1827492T3 (en) | 2004-11-30 | 2010-11-22 | Curagen Corp | Antibodies targeting GPNMB and uses thereof |
US8165517B2 (en) | 2005-01-19 | 2012-04-24 | The Trustees Of The University Of Pennsylvania | Methods for identifying inhibitors of vascular injury |
AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
CA2612762C (en) * | 2005-06-20 | 2013-12-10 | Psma Development Company, Llc | Psma antibody-drug conjugates |
USRE47223E1 (en) | 2005-06-20 | 2019-02-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP3498289A1 (en) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
CN101505800A (en) * | 2005-07-08 | 2009-08-12 | 艾伦药物公司 | Preparation of pegylated conjugates of VLA-4 antagonists via a Mitsunobu's reaction |
LT1912671T (en) | 2005-07-18 | 2017-12-11 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
AU2006294663B2 (en) * | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
AR059900A1 (en) | 2006-03-17 | 2008-05-07 | Genentech Inc | ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS |
SG172604A1 (en) * | 2006-05-22 | 2011-07-28 | Elan Pharm Inc | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
RU2436796C9 (en) | 2006-05-30 | 2013-12-27 | Дженентек, Инк. | Antibodies and immunoconjugates and their application |
US8257706B2 (en) * | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
KR101541550B1 (en) | 2006-10-27 | 2015-08-04 | 제넨테크, 인크. | Antibodies and immunoconjugates and uses therefor |
EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
KR20090088946A (en) * | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | Human antibodies that bind cd70 and uses thereof |
CN104013956B (en) * | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR |
RU2009133784A (en) | 2007-02-09 | 2011-03-20 | Дженентек, Инк. (Us) | ANTI-Robo4-ANTIBODIES AND THEIR APPLICATIONS |
WO2008115404A1 (en) * | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
WO2008118970A2 (en) | 2007-03-27 | 2008-10-02 | Sea Lane Biotechnologies, Llc | Constructs and libraries comprising antibody surrogate light chain sequences |
GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
WO2008141044A2 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
ES2381788T3 (en) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anti-CD79b and immunoconjugate antibodies and methods of use |
SG183044A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugatesand methods of use |
US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
MX2010001757A (en) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof. |
PT2187965T (en) | 2007-08-17 | 2020-01-17 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
CA2697992C (en) | 2007-10-04 | 2017-08-22 | Zymogenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
NZ584552A (en) * | 2007-10-12 | 2012-07-27 | Seattle Genetics Inc | Combination therapy comprising brentuximab and either a AVBD regimen or gemcitabine |
HUE031533T2 (en) | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | Cd19 binding agents and uses thereof |
WO2009067546A2 (en) | 2007-11-19 | 2009-05-28 | Celera Corpration | Lung cancer markers and uses thereof |
EP2078492A1 (en) * | 2008-01-11 | 2009-07-15 | Roche Diagnostics GmbH | Tape cassette for a medical hand device and blood sugar measuring system |
ES2613963T3 (en) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Cysteine manipulated antibodies for site specific conjugation |
UA106586C2 (en) | 2008-01-31 | 2014-09-25 | Дженентек, Інк. | Anti-cd79b antibodies and imunokonugate and methods for their use |
CA2718942A1 (en) * | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
SG189776A1 (en) | 2008-04-11 | 2013-05-31 | Seattle Genetics Inc | Detection and treatment of pancreatic, ovarian and other cancers |
KR101764081B1 (en) | 2008-04-30 | 2017-08-01 | 이뮤노젠 아이엔씨 | Cross-linkers and their uses |
EP2282773B1 (en) | 2008-05-02 | 2014-01-15 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
EP2727606A3 (en) | 2008-09-08 | 2015-09-23 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
UA109633C2 (en) | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
JP5823874B2 (en) | 2009-01-09 | 2015-11-25 | シアトル ジェネティクス,インコーポレーテッド | Weekly dosing schedule of anti-CD30vc-PAB-MMAE antibody-drug conjugate |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
CA2754531A1 (en) * | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
AU2010249046A1 (en) | 2009-05-13 | 2011-12-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to influenza viruses |
KR102560218B1 (en) | 2009-06-03 | 2023-07-26 | 이뮤노젠 아이엔씨 | Conjugation methods |
BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011038159A2 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
EP2486023A4 (en) | 2009-10-06 | 2014-05-07 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
CA3031851C (en) | 2009-10-23 | 2020-07-07 | Amgen British Columbia | Anti-gcc antibody molecules and related compositions and methods |
CN102741294A (en) | 2009-11-30 | 2012-10-17 | 霍夫曼-拉罗奇有限公司 | Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID 2) |
PL2510011T3 (en) | 2009-12-09 | 2015-02-27 | Inst Nat Sante Rech Med | Monoclonal antibodies that bind b7h6 and uses thereof |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
TWI504410B (en) | 2010-02-08 | 2015-10-21 | Agensys Inc | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
PE20130214A1 (en) | 2010-02-23 | 2013-03-11 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
PT2542576T (en) * | 2010-03-02 | 2016-07-14 | Seattle Genetics Inc | Methods for screening antibodies |
MX365521B (en) | 2010-04-15 | 2019-06-06 | Oligasis Star | High molecular weight zwitterion-containing polymers. |
AU2011239522B2 (en) | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
EP2789622B1 (en) | 2010-04-15 | 2017-03-01 | MedImmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
KR20130098165A (en) | 2010-06-03 | 2013-09-04 | 제넨테크, 인크. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
JP2013534520A (en) | 2010-06-08 | 2013-09-05 | ジェネンテック, インコーポレイテッド | Cysteine engineered antibodies and conjugates |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
ES2528956T3 (en) | 2010-06-10 | 2015-02-13 | Seattle Genetics, Inc. | New derivatives of auristatin and its use |
WO2011157741A2 (en) | 2010-06-15 | 2011-12-22 | Genmab A/S | Human antibody drug conjugates against tissue factor |
JP5953303B2 (en) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | Antibodies with modified isoelectric points |
KR102504750B1 (en) | 2010-09-29 | 2023-03-02 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
US8987209B2 (en) | 2010-09-29 | 2015-03-24 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatin and the use thereof |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
EP3581206A1 (en) | 2010-10-22 | 2019-12-18 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway |
SG10201510041QA (en) | 2010-12-06 | 2016-01-28 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
NZ610976A (en) | 2010-12-20 | 2015-07-31 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
CA2824143C (en) | 2011-01-14 | 2018-12-18 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
WO2012123423A1 (en) | 2011-03-16 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatins and use thereof |
AU2012228100B2 (en) | 2011-03-17 | 2016-09-08 | The University Of Birmingham | Re-directed immunotherapy |
EP2690955A4 (en) | 2011-03-30 | 2014-10-15 | Univ Arizona | Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof |
JP6177231B2 (en) | 2011-04-20 | 2017-08-09 | ゲンマブ エー/エス | Bispecific antibody against HER2 |
US20130122024A1 (en) | 2011-04-21 | 2013-05-16 | Bayer Intellectual Property Gmbh | New binder-drug conjugates (adcs) and use thereof |
EP2707723B1 (en) | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
ES2643694T3 (en) | 2011-05-19 | 2017-11-23 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Human anti-HER3 antibodies and their uses |
EP2710024A4 (en) | 2011-05-19 | 2015-04-29 | Harvard College | Osw-1 analogs and conjugates, and uses thereof |
DK2714684T3 (en) * | 2011-05-27 | 2018-11-26 | Ambrx Inc | COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES |
ES2898854T3 (en) * | 2011-05-27 | 2022-03-09 | Ambrx Inc | Compositions Containing, Methods Involving, and Uses of Unnatural Amino Acid Linked Dolastatin Derivatives |
UA112434C2 (en) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | ANTIGENCY BINDING SPECIFICALLY Binds to ALL |
BR112013028779B8 (en) | 2011-05-27 | 2021-04-20 | Glaxo Group Ltd | antigen-binding protein or immunoconjugate, immunoconjugate, pharmaceutical composition, and, use of a composition |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
KR101972303B1 (en) | 2011-06-10 | 2019-04-25 | 메르사나 테라퓨틱스, 인코포레이티드 | Protein-Polymer-Drug Conjugates |
MX350954B (en) | 2011-06-21 | 2017-09-26 | Immunogen Inc | Novel maytansinoid derivatives with peptide linker and conjugates thereof. |
EP2723377B1 (en) | 2011-06-22 | 2018-06-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2012175691A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
CA2842860A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies, Llc | Sur-binding proteins |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
CN108152513B (en) | 2011-09-29 | 2020-07-24 | 西雅图基因公司 | Overall molecular weight determination of protein-coupled reagent compounds |
CA3182462A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
EA028457B1 (en) | 2011-10-14 | 2017-11-30 | Медимьюн Лимитед | Pyrrolobenzodiazepines |
CN103998449A (en) | 2011-10-14 | 2014-08-20 | 斯皮罗根有限公司 | Pyrrolobenzodiazepines |
ES2687246T3 (en) | 2011-10-14 | 2018-10-24 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and directed conjugates |
BR112014012609A2 (en) | 2011-11-17 | 2020-10-20 | Pfizer Inc | cytotoxic and conjugated antibody drug peptides thereof |
MX2014006739A (en) * | 2011-12-05 | 2015-06-05 | Igenica Biotherapeutics Inc | Antibody-drug conjugates and related compounds, compositions, and methods. |
EP2793940B1 (en) | 2011-12-22 | 2018-11-14 | i2 Pharmaceuticals, Inc. | Surrogate binding proteins |
ES2721882T3 (en) | 2011-12-23 | 2019-08-06 | Pfizer | Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof |
EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
CN104169850B (en) | 2012-01-12 | 2017-06-06 | 辛纳普蒂克斯公司 | Individual layer capacitive character imaging sensor |
CA2862292C (en) | 2012-01-20 | 2019-10-08 | Sea Lane Biotechnologies, Llc | Binding molecule conjugates |
ES2725569T3 (en) | 2012-02-10 | 2019-09-24 | Seattle Genetics Inc | Diagnosis and treatment of cancers that express CD30 |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
TW201402609A (en) | 2012-05-01 | 2014-01-16 | Genentech Inc | Anti-PMEL17 antibodies and immunoconjugates |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
KR102475777B1 (en) | 2012-05-15 | 2022-12-09 | 씨젠 인크. | Self-stabilizing linker conjugates |
US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
US8822423B2 (en) * | 2012-05-17 | 2014-09-02 | Janssen Biotech, Inc. | Affinity peptides toward infliximab |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
SG11201407561UA (en) | 2012-05-21 | 2014-12-30 | Genentech Inc | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE |
US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
JP2015521589A (en) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Procoagulant compounds |
CA2875989A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | Chimeric clotting factors |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
CN112587671A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
DK2692865T3 (en) | 2012-07-30 | 2015-02-16 | Nbe Therapeutics Llc | Transponeringsmedieret identification of specific binding proteins, or functional |
JP2015529656A (en) | 2012-08-02 | 2015-10-08 | ジェネンテック, インコーポレイテッド | Anti-ETBR antibodies and immune complexes |
MX2015001399A (en) | 2012-08-02 | 2015-09-07 | Genentech Inc | Anti-etbr antibodies and immunoconjugates. |
CA2882745C (en) | 2012-08-23 | 2022-03-29 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
HUE045227T2 (en) | 2012-08-31 | 2019-12-30 | Sutro Biopharma Inc | Modified amino acids comprising an azido group |
WO2014057072A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
ES2660029T3 (en) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Antibody-pyrrolobenzodiazepine conjugates |
SI2906251T1 (en) | 2012-10-12 | 2018-01-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
HUE052835T2 (en) | 2012-10-12 | 2021-05-28 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
CN105050661B (en) | 2012-10-12 | 2018-03-30 | Adc疗法责任有限公司 | Pyrrolobenzodiazepines Zhuo antibody conjugates |
DK2906296T3 (en) | 2012-10-12 | 2018-05-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
BR112015008173A2 (en) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | pyrrolobenzodiazepine-anti-psma antibody conjugates |
HUE045435T2 (en) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
SG11201502896XA (en) * | 2012-10-16 | 2015-05-28 | Endocyte Inc | Drug delivery conjugates containing unnatural amino acids and methods for using |
US9556192B2 (en) | 2012-10-30 | 2017-01-31 | Nerviano Medical Sciences S.R.L. | Functionalized 9-bromo-camptothecin derivatives |
CA2889764C (en) | 2012-11-01 | 2023-10-10 | Martin Lipp | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
EP2917195B9 (en) | 2012-11-05 | 2018-05-30 | Pfizer Inc | Spliceostatin analogs |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
JP6892218B2 (en) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドEndocyte, Inc. | How to treat diseases caused by drug delivery conjugates and PSMA-expressing cells |
JP6133431B2 (en) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | Use of hydrophilic conjugates and conjugation reactions between drug molecules and cell binding molecules |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
AU2013359506B2 (en) | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
EP2928503B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugates of auristatin compounds |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
KR102272233B1 (en) | 2012-12-12 | 2021-07-01 | 프로메가 코포레이션 | Compositions and methods for capture of cellular targets of bioactive agents |
EP2934596A1 (en) | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
MY169117A (en) | 2012-12-21 | 2019-02-18 | Bioalliance Cv | Hydrophilic self-immolative linkers and conjugates thereof |
WO2014100740A1 (en) | 2012-12-21 | 2014-06-26 | Seattle Genetics, Inc. | Anti-ntb-a antibodies and related compositions and methods |
CN113735967A (en) | 2013-01-10 | 2021-12-03 | 根马布私人有限公司 | Human IgG1 FC region variants and uses thereof |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
CA3211863A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
WO2014134486A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6494533B2 (en) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | Complexes comprising maytansinoids as cell binding agents and cytotoxic agents |
EP3299391B1 (en) | 2013-03-14 | 2019-12-04 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
SG11201507619PA (en) | 2013-03-15 | 2015-10-29 | Ct For Drug Res And Dev | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
US10168323B2 (en) | 2013-03-15 | 2019-01-01 | Promega Corporation | Compositions and methods for capture of cellular targets of bioactive agents |
WO2014143765A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Deutschland Gmbh & Co.Kg | Anti-egfr antibody drug conjugate formulations |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
CN111138543A (en) | 2013-03-15 | 2020-05-12 | Xencor股份有限公司 | Heterodimeric proteins |
RU2015144186A (en) | 2013-03-15 | 2017-04-24 | Эббви Инк. | CLEANING THE ANTIBODY MEDICINE (ADC) CONJUGATE |
CA3093606A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US11072811B2 (en) | 2013-03-15 | 2021-07-27 | Promega Corporation | Substrates for covalent tethering of proteins to functional groups or solid surfaces |
DK2991683T3 (en) | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC CHARGE |
MX369758B (en) | 2013-05-31 | 2019-11-20 | Genentech Inc | Anti-wall teichoic antibodies and conjugates. |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
RS60256B1 (en) | 2013-05-31 | 2020-06-30 | Genentech Inc | Anti-wall teichoic antibodies and conjugates |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
AU2014274982B2 (en) | 2013-06-04 | 2019-12-05 | Cytomx Therapeutics, Inc | Compositions and methods for conjugating activatable antibodies |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP3010548A1 (en) | 2013-06-21 | 2016-04-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
EP3027220A1 (en) | 2013-08-01 | 2016-06-08 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
US9552089B2 (en) | 2013-08-07 | 2017-01-24 | Synaptics Incorporated | Capacitive sensing using a matrix electrode pattern |
TWI636792B (en) | 2013-08-12 | 2018-10-01 | 建南德克公司 | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
PE20160674A1 (en) | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | METHODS OF CONJUGATION OF SITE-SPECIFIC ANTIBODIES AND COMPOSITIONS |
SG11201601770YA (en) | 2013-09-12 | 2016-04-28 | Halozyme Inc | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
CN105518027A (en) | 2013-09-17 | 2016-04-20 | 豪夫迈·罗氏有限公司 | Methods of using anti-LGR5 antibodies |
US9298325B2 (en) | 2013-09-30 | 2016-03-29 | Synaptics Incorporated | Processing system for a capacitive sensing device |
US10042489B2 (en) | 2013-09-30 | 2018-08-07 | Synaptics Incorporated | Matrix sensor for image touch sensing |
US20150091842A1 (en) | 2013-09-30 | 2015-04-02 | Synaptics Incorporated | Matrix sensor for image touch sensing |
US9459367B2 (en) | 2013-10-02 | 2016-10-04 | Synaptics Incorporated | Capacitive sensor driving technique that enables hybrid sensing or equalization |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
KR102087850B1 (en) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | Protein-Polymer-Drug Conjugates |
JP6502931B2 (en) | 2013-10-11 | 2019-04-17 | アメリカ合衆国 | TEM 8 antibody and use thereof |
CN105813655B (en) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | Protein-polymer-drug conjugates |
EA036927B1 (en) | 2013-10-11 | 2021-01-15 | Оксфорд Биотерепьютикс Лтд | Conjugated antibodies against ly75 for the treatment of cancer |
IL293071A (en) * | 2013-10-15 | 2022-07-01 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
AU2014337317A1 (en) | 2013-10-15 | 2016-09-15 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
EP3415489A1 (en) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US9274662B2 (en) | 2013-10-18 | 2016-03-01 | Synaptics Incorporated | Sensor matrix pad for performing multiple capacitive sensing techniques |
SG11201603125SA (en) | 2013-10-21 | 2016-05-30 | Genentech Inc | ANTI-Ly6E ANTIBODIES AND METHODS OF USE |
US9495046B2 (en) | 2013-10-23 | 2016-11-15 | Synaptics Incorporated | Parasitic capacitance filter for single-layer capacitive imaging sensors |
US9081457B2 (en) | 2013-10-30 | 2015-07-14 | Synaptics Incorporated | Single-layer muti-touch capacitive imaging sensor |
WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
US10196455B2 (en) | 2013-11-07 | 2019-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuregulin allosteric anti-HER3 antibody |
US10457976B2 (en) | 2013-11-25 | 2019-10-29 | Seattle Genetics, Inc. | Preparing antibodies from CHO cell cultures for conjugation |
WO2015085289A1 (en) | 2013-12-06 | 2015-06-11 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
EP3080164B1 (en) | 2013-12-13 | 2019-01-16 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
MX2016007578A (en) | 2013-12-16 | 2016-10-03 | Genentech Inc | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment. |
KR102442906B1 (en) | 2013-12-19 | 2022-09-14 | 씨젠 인크. | Methylene carbamate linkers for use with targeted-drug conjugates |
EP4212181A3 (en) | 2013-12-19 | 2023-11-15 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
CN106255513B (en) | 2013-12-27 | 2022-01-14 | 酵活有限公司 | Sulfonamide-containing linking systems for drug conjugates |
CA2935064C (en) | 2013-12-27 | 2023-06-27 | Zymeworks Inc. | Var2csa-drug conjugates |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2015103989A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for immunotherapy |
WO2015108998A2 (en) | 2014-01-15 | 2015-07-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Cartilage targeting agents and their use |
EP3096797A1 (en) | 2014-01-24 | 2016-11-30 | F. Hoffmann-La Roche AG | Methods of using anti-steap1 antibodies and immunoconjugates |
RU2685728C2 (en) | 2014-01-29 | 2019-04-23 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Ligand-cytotoxic drug conjugate, production method and use thereof |
FR3017298B1 (en) | 2014-02-07 | 2016-03-04 | Centre Nat Rech Scient | CONJUGATES AND PRO-DRUGS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES |
EP4190809A1 (en) | 2014-02-11 | 2023-06-07 | Seagen Inc. | Selective reduction of proteins |
CA2937753A1 (en) * | 2014-02-17 | 2015-08-20 | Seattle Genetics, Inc. | Hydrophilic antibody-drug conjugates |
WO2015127407A1 (en) | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
PT3122757T (en) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Charged linkers and their uses for conjugation |
US9798429B2 (en) | 2014-02-28 | 2017-10-24 | Synaptics Incorporated | Guard electrodes in a sensing stack |
RU2020124944A (en) | 2014-03-21 | 2020-08-27 | Эббви Инк. | ANTIBODIES AGAINST EGFR AND ANTIBODY-DRUG CONJUGATES |
SG10202008629XA (en) | 2014-03-28 | 2020-10-29 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
US10133421B2 (en) | 2014-04-02 | 2018-11-20 | Synaptics Incorporated | Display stackups for matrix sensor |
US9260478B2 (en) | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
FR3020063A1 (en) | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | ANTI-HER4 HUMAN ANTIBODY |
US9927832B2 (en) | 2014-04-25 | 2018-03-27 | Synaptics Incorporated | Input device having a reduced border region |
US9690397B2 (en) | 2014-05-20 | 2017-06-27 | Synaptics Incorporated | System and method for detecting an active pen with a matrix sensor |
EP3166638A1 (en) | 2014-06-13 | 2017-05-17 | Glykos Finland Oy | Payload-polymer-protein conjugates |
EP3154587B1 (en) | 2014-06-13 | 2020-01-15 | Tenboron OY | Conjugates comprising an anti-egfr1 antibody |
US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
WO2015197919A1 (en) | 2014-06-25 | 2015-12-30 | Glykos Finland Oy | Antibody drug conjugates binding to high-mannose n-glycan |
EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
LT3169706T (en) | 2014-07-11 | 2020-03-25 | Genmab A/S | Antibodies binding axl |
WO2016008112A1 (en) | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
US20160060360A1 (en) | 2014-07-24 | 2016-03-03 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
BR112017001403A2 (en) | 2014-07-24 | 2017-11-21 | Genentech Inc | methods for conjugating an agent with a thiol moiety to a protein containing at least one trisulfide bond |
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
CN112587672A (en) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | anti-PD-L1 conjugates for the treatment of tumors |
CN114732916B (en) | 2014-09-11 | 2023-12-19 | 西雅图基因公司 | Targeted delivery of tertiary amine-containing drug substances |
CN113698485A (en) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | anti-B7-H4 antibodies and immunoconjugates |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
AR101844A1 (en) | 2014-09-12 | 2017-01-18 | Genentech Inc | ANTIBODIES AND GENETICALLY MODIFIED CONJUGATES WITH CYSTEINE |
JP6886398B2 (en) | 2014-09-12 | 2021-06-16 | ジェネンテック, インコーポレイテッド | ANTI-CLL-1 antibody and immune complex |
SG11201701623UA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
CA2960899C (en) | 2014-09-17 | 2021-08-17 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
JP2017537893A (en) | 2014-10-31 | 2017-12-21 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Anti-CS1 antibody and antibody drug conjugate |
CN107001384A (en) | 2014-11-05 | 2017-08-01 | 内尔维阿诺医学科学有限公司 | The morpholinyl anthracycline derivative of functionalization |
LT3221349T (en) | 2014-11-19 | 2021-02-10 | Axon Neuroscience Se | Humanized tau antibodies in alzheimer's disease |
CN104609464B (en) * | 2014-11-21 | 2017-01-04 | 中国科学院电工研究所 | A kind of preparation method of PbS nanometer sheet |
BR112017011111A2 (en) | 2014-11-25 | 2017-12-26 | Adc Therapeutics Sa | pyrrolobenzodiazepine-antibody conjugates |
LT3223845T (en) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
EA037065B1 (en) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Heterodimeric antibodies that bind cd3 and cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
RU2017118792A (en) | 2014-12-03 | 2019-01-09 | Дженентек, Инк. | ANTIBODY CONJUGATES TO STAPHYLOCOCCUS AUREUS WITH RIFAMICINE AND THEIR APPLICATION |
RU2731055C2 (en) | 2014-12-03 | 2020-08-28 | Дженентек, Инк. | Conjugates of antibodies to staphylococcus aureus with rifamycin and use thereof |
SG11201704710PA (en) | 2014-12-09 | 2017-07-28 | Abbvie Inc | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
CN113209306A (en) | 2014-12-09 | 2021-08-06 | 艾伯维公司 | Antibody drug conjugates with cell permeable BCL-XL inhibitors |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
US10175827B2 (en) | 2014-12-23 | 2019-01-08 | Synaptics Incorporated | Detecting an active pen using a capacitive sensing device |
US9778713B2 (en) | 2015-01-05 | 2017-10-03 | Synaptics Incorporated | Modulating a reference voltage to preform capacitive sensing |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
MX2017009144A (en) | 2015-01-14 | 2017-11-22 | Bristol Myers Squibb Co | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using. |
WO2016115191A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
GB201501004D0 (en) | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
EP4137159A1 (en) * | 2015-01-28 | 2023-02-22 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
TW201702260A (en) | 2015-03-05 | 2017-01-16 | 賽倫斯有限責任公司 | Cyclic peptide analogs and conjugates thereof |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
TWI719967B (en) | 2015-03-09 | 2021-03-01 | 美商艾澤西公司 | Antibody drug conjugates (adc) that bind to flt3 proteins |
EP3270965B1 (en) | 2015-03-18 | 2020-05-06 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
US9939972B2 (en) | 2015-04-06 | 2018-04-10 | Synaptics Incorporated | Matrix sensor with via routing |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CN106188293A (en) * | 2015-04-17 | 2016-12-07 | 江苏恒瑞医药股份有限公司 | Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof |
EP3091033A1 (en) | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
EP3295171A1 (en) | 2015-05-12 | 2018-03-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof |
US10526415B2 (en) | 2015-05-22 | 2020-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor |
EP3303391A1 (en) | 2015-05-26 | 2018-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas |
WO2016189118A1 (en) | 2015-05-28 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of prognosis and treatment of patients suffering from acute myeloid leukemia |
CA2989347A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
MX2017015814A (en) | 2015-06-23 | 2018-04-10 | Squibb Bristol Myers Co | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses. |
US10095948B2 (en) | 2015-06-30 | 2018-10-09 | Synaptics Incorporated | Modulation scheme for fingerprint sensing |
IL303690A (en) | 2015-06-30 | 2023-08-01 | Seagen Inc | Anti-ntb-a antibodies and related compositions and methods |
US9720541B2 (en) | 2015-06-30 | 2017-08-01 | Synaptics Incorporated | Arrangement of sensor pads and display driver pads for input device |
US9715304B2 (en) | 2015-06-30 | 2017-07-25 | Synaptics Incorporated | Regular via pattern for sensor-based input device |
CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
CN113350518A (en) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | Conjugated bridge linkers to cell binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
IL257065B (en) | 2015-07-22 | 2022-07-01 | Inatherys | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |
CN205028263U (en) | 2015-09-07 | 2016-02-10 | 辛纳普蒂克斯公司 | Capacitance sensor |
US10037112B2 (en) | 2015-09-30 | 2018-07-31 | Synaptics Incorporated | Sensing an active device'S transmission using timing interleaved with display updates |
WO2017058808A1 (en) | 2015-10-02 | 2017-04-06 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
US10392441B2 (en) | 2015-10-07 | 2019-08-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
AU2016335848B2 (en) | 2015-10-09 | 2020-12-17 | Miltenyi Biotec Technology, Inc. | Chimeric antigen receptors and methods of use |
WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
EP3362088B1 (en) | 2015-10-12 | 2020-11-25 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
WO2017067944A1 (en) | 2015-10-19 | 2017-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from triple negative breast cancer |
JP6486316B2 (en) * | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Industrial Technology Research Institute | Antibody-drug conjugate (ADC) and method for forming the same |
PL3377103T3 (en) | 2015-11-19 | 2021-10-04 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
JP2019501124A (en) | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
US10188660B2 (en) | 2015-11-30 | 2019-01-29 | Abbvie Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
US10067587B2 (en) | 2015-12-29 | 2018-09-04 | Synaptics Incorporated | Routing conductors in an integrated display device and sensing device |
CN106933400B (en) | 2015-12-31 | 2021-10-29 | 辛纳普蒂克斯公司 | Single layer sensor pattern and sensing method |
ES2880731T3 (en) | 2016-01-08 | 2021-11-25 | Altrubio Inc | Quadrivalent anti-PSGL-1 antibodies and uses thereof |
MX2018008300A (en) | 2016-01-13 | 2018-09-21 | Genmab As | Formulation for antibody and drug conjugate thereof. |
RU2766190C2 (en) | 2016-01-20 | 2022-02-09 | Дзе Скриппс Рисерч Инститьют | Compositions of antibodies against ror1 and corresponding methods |
MA43094B1 (en) * | 2016-01-25 | 2020-10-28 | Regeneron Pharma | Maytansinoid derivatives, their conjugates, and methods of use |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
US11708413B2 (en) | 2016-01-27 | 2023-07-25 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
ES2946073T3 (en) | 2016-02-05 | 2023-07-12 | Rigshospitalet | Antibody-drug conjugates targeting uPARAP |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US20170233484A1 (en) | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
US11191821B2 (en) | 2016-02-27 | 2021-12-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptide vaccine formulations and use thereof for inducing an immune response |
US20190060473A1 (en) | 2016-02-29 | 2019-02-28 | Madrigal Pharmaceuticals, Inc. | Hsp90 inhibitor drug conjugates |
KR102445255B1 (en) * | 2016-03-02 | 2022-09-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Eribulin-Based Antibody-Drug Conjugates and Methods of Use |
BR112018014355A2 (en) | 2016-03-04 | 2018-12-18 | Genentech, Inc. | processes for the preparation of f-benzoxazinorifamycin i and for the preparation of 2-amino-5-fluorobenzene-1,3-diol iii |
MA45324A (en) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
EP3433272A1 (en) | 2016-03-22 | 2019-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Humanized anti-claudin-1 antibodies and uses thereof |
JP7123399B2 (en) | 2016-03-24 | 2022-08-23 | ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | Conjugates of tacrolimus, compositions thereof and uses thereof |
WO2017165851A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
DK3438118T3 (en) | 2016-03-29 | 2023-05-30 | Toray Industries | Peptide derivative and use thereof |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
IL308504A (en) | 2016-05-13 | 2024-01-01 | Bioatla Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP4233909A3 (en) | 2016-05-17 | 2023-09-20 | AbbVie Biotherapeutics Inc. | Anti-cmet antibody drug conjugates and methods for their use |
US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
EP3464294B1 (en) | 2016-05-30 | 2022-07-13 | Toxinvent Oü | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
JP2019524649A (en) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | Anti-CD98 antibodies and antibody drug conjugates |
AU2017277534A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
JP2019521973A (en) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | Anti-BH7-H3 antibody and antibody drug conjugate |
CR20180614A (en) | 2016-06-08 | 2019-07-29 | Abbvie Inc | CONJUGATES OF ANTIBODY AND ANTI-EGFR DRUG |
WO2017214458A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
CA3027173A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
CN109963870B (en) | 2016-06-08 | 2023-07-28 | 艾伯维公司 | anti-B7-H3 antibodies and antibody drug conjugates |
JP2019526529A (en) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | Anti-B7-H3 antibody and antibody drug conjugate |
US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
CN106674347B (en) * | 2016-08-16 | 2019-12-13 | 滨州医学院 | Novel auristatin antibody |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018045245A1 (en) | 2016-09-02 | 2018-03-08 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
CN109843922B (en) | 2016-09-02 | 2023-10-03 | 莱蒂恩技术公司 | Compositions and methods for treating cancer with DuoCAR |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
MX2019004327A (en) | 2016-10-14 | 2019-10-14 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments. |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
KR20190074292A (en) | 2016-10-18 | 2019-06-27 | 시애틀 지네틱스, 인크. | Targeted delivery of remedial pathway inhibitors of nicotinamide adenine dinucleotides |
EP3529269A2 (en) | 2016-10-19 | 2019-08-28 | Invenra, Inc. | Antibody constructs |
WO2018077926A1 (en) | 2016-10-25 | 2018-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Monoclonal antibodies binding to the cd160 transmembrane isoform |
RU2766586C2 (en) | 2016-10-28 | 2022-03-15 | Торэй Индастриз, Инк. | Pharmaceutical composition for treatment and/or prevention of malignant tumor |
EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
CN116143678A (en) | 2016-11-14 | 2023-05-23 | 杭州多禧生物科技有限公司 | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof |
US11464869B2 (en) | 2016-11-14 | 2022-10-11 | Takeda Pharmaceutical Company Limited | Non-adult human dosing of brentuximab vedotin |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
JP7244987B2 (en) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | Multidrug Antibody Drug Conjugates |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
KR102015524B1 (en) * | 2016-12-26 | 2019-08-29 | 인터올리고 주식회사 | [GRO Aptamer]-Drug Conjugates And Use Thereof |
CN106854245A (en) * | 2016-12-28 | 2017-06-16 | 无锡傲锐东源生物科技有限公司 | Protein monoclonal antibody of AntiCD3 McAb 0 and application thereof |
JP6706394B1 (en) | 2017-01-09 | 2020-06-03 | レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. | Compositions and methods for treating cancer by anti-mesothelin immunotherapy |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
DK3544636T3 (en) | 2017-02-08 | 2021-05-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine antibody conjugates |
JP7341060B2 (en) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for the treatment of cancer associated with MAPK pathway activation |
NZ756674A (en) | 2017-02-16 | 2023-06-30 | Sonnet Biotherapeutics Inc | Albumin binding domain fusion proteins |
WO2018158716A1 (en) | 2017-03-02 | 2018-09-07 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
CA3057838A1 (en) | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
CA3055132A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
JP7284707B2 (en) | 2017-04-07 | 2023-05-31 | ジュノー セラピューティクス インコーポレイテッド | Engineered Cells Expressing Prostate-Specific Membrane Antigen (PSMA) or Modified Forms Thereof and Related Methods |
DK3612537T3 (en) | 2017-04-18 | 2022-08-08 | Medimmune Ltd | PYRROLOBENZODIAZEPIN CONJUGATES |
WO2018195302A1 (en) | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
JOP20190254A1 (en) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | Antitumoral compounds |
CN110799217A (en) | 2017-04-27 | 2020-02-14 | 西雅图基因公司 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
KR20200002858A (en) | 2017-04-28 | 2020-01-08 | 아지노모토 가부시키가이샤 | Compounds having affinity, cleavable moieties and reactive groups for soluble proteins or salts thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US11666657B2 (en) | 2017-05-16 | 2023-06-06 | Universite De Strasbourg | Protein-drug conjugates and their use in the treatment of cancers |
KR20200007905A (en) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cyclodextrin protein drug conjugate |
KR102442736B1 (en) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | Dosage regime for administration of anti-CD19 ADCs |
CN108452321B (en) * | 2017-06-19 | 2021-11-26 | 四川百利药业有限责任公司 | Antibody-drug conjugate with acidic self-stabilizing joint |
CN111315414A (en) | 2017-06-22 | 2020-06-19 | 梅尔莎纳医疗公司 | Methods of producing drug-loaded polymer scaffolds and protein-polymer-drug conjugates |
US20210403573A1 (en) | 2017-06-22 | 2021-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells |
TWI804499B (en) | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1 antibody immunoconjugates |
WO2019005756A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | Anti-mertk agonistic antibody-drug conjugates and uses thereof |
MA49517A (en) | 2017-06-30 | 2020-05-06 | Xencor Inc | TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING |
EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
JP7237926B2 (en) | 2017-07-31 | 2023-03-13 | レンティジェン・テクノロジー・インコーポレイテッド | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
KR102312910B1 (en) | 2017-08-18 | 2021-10-15 | 메디뮨 리미티드 | Pyrrolobenzodiazepine conjugates |
JP7035170B2 (en) | 2017-09-15 | 2022-03-14 | レンティジェン・テクノロジー・インコーポレイテッド | Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy |
SG11202002310UA (en) | 2017-09-18 | 2020-04-29 | Sutro Biopharma Inc | Anti- folate receptor alpha antibody conjugates and their uses |
KR20200066676A (en) | 2017-10-11 | 2020-06-10 | 시애틀 지네틱스, 인크. | How to reduce the side effects of anti-CD30 antibody drug conjugate therapy |
US11332527B2 (en) | 2017-10-12 | 2022-05-17 | Keio University | Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US10543263B2 (en) | 2017-10-16 | 2020-01-28 | Lentigen Technology Inc. | Compositions and methods for treating cancer with anti-CD22 immunotherapy |
CN107759699A (en) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | Target transgenic T cells of CD30 antigens and preparation method and application |
EP3703761A1 (en) | 2017-11-01 | 2020-09-09 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US20200363425A1 (en) * | 2017-11-22 | 2020-11-19 | Seattle Genetics, Inc. | Acid-mediated assay for analyzing ligand-drug conjugates |
CN111727075B (en) | 2017-11-27 | 2024-04-05 | 普渡制药公司 | Humanized antibodies targeting human tissue factor |
BR112020010816A2 (en) * | 2017-11-29 | 2020-11-10 | Magenta Therapeutics, Inc. | compositions and methods for the depletion of cd2 + cells |
SG11202004864TA (en) | 2017-12-01 | 2020-06-29 | Seattle Genetics Inc | Cd47 antibodies and uses thereof for treating cancer |
CN111757892A (en) | 2017-12-01 | 2020-10-09 | 西雅图基因公司 | Humanized anti-LIV 1 antibodies for the treatment of breast cancer |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
SG11202005732XA (en) | 2017-12-19 | 2020-07-29 | Xencor Inc | Engineered il-2 fc fusion proteins |
US10894819B2 (en) | 2017-12-20 | 2021-01-19 | Lentigen Technology, Inc. | Compositions and methods for treating HIV/AIDS with immunotherapy |
AU2019225845A1 (en) * | 2018-02-20 | 2020-09-24 | Seagen Inc. | Hydrophobic Auristatin F compounds and conjugates thereof |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
CN112088168A (en) | 2018-03-07 | 2020-12-15 | 柏林合作研究学会 | Chemoselective thiol coupling with alkene-or alkyne-thiophosphonates and-phosphonates |
WO2019173911A1 (en) | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
AU2019240403A1 (en) | 2018-03-23 | 2020-10-08 | Seagen Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3552631A1 (en) | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
US20210308207A1 (en) | 2018-05-04 | 2021-10-07 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
AU2019262520A1 (en) | 2018-05-04 | 2021-01-14 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
US11396497B2 (en) | 2018-05-04 | 2022-07-26 | New Mexico Tech University Research Park Corporation | Proteasome inhibitors |
CA3099547A1 (en) | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
MX2020011176A (en) | 2018-05-07 | 2020-11-12 | Genmab As | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate. |
EP3790899A1 (en) | 2018-05-09 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
EP3802580A1 (en) | 2018-06-05 | 2021-04-14 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
WO2019240288A1 (en) | 2018-06-14 | 2019-12-19 | 味の素株式会社 | Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
JP7413999B2 (en) | 2018-06-14 | 2024-01-16 | 味の素株式会社 | Compounds having affinity for antibodies, cleavable moieties, and reactive groups, or salts thereof |
CR20210047A (en) | 2018-07-02 | 2021-05-21 | Amgen Inc | ANTI-STEAP1 ANTIGEN BINDING PROTEIN |
JP2021533102A (en) | 2018-07-27 | 2021-12-02 | プロメガ コーポレイションPromega Corporation | Quinone-containing complex |
SG11202102427XA (en) | 2018-09-11 | 2021-04-29 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
JP2022500454A (en) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | Combination therapy with antifolate receptor antibody conjugate |
JP2022511337A (en) | 2018-09-19 | 2022-01-31 | インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) | Methods and Pharmaceutical Compositions for the Treatment of Cancers Resistant to Immune Checkpoint Treatment |
JP2022501043A (en) | 2018-09-20 | 2022-01-06 | レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy |
EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
JP2022511351A (en) | 2018-09-26 | 2022-01-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Laboratory animal ligand-drug conjugation, its preparation method and its application |
US10822412B2 (en) | 2018-09-26 | 2020-11-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy |
US20200102399A1 (en) | 2018-10-01 | 2020-04-02 | Seattle Genetics, Inc. | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
EP3867265A1 (en) | 2018-10-19 | 2021-08-25 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
TWI824043B (en) | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | Drug antibody conjugates |
CA3117050A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
TW202034958A (en) | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
WO2020090979A1 (en) | 2018-10-31 | 2020-05-07 | 味の素株式会社 | Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof |
EP3647419A1 (en) | 2018-11-02 | 2020-05-06 | NBE Therapeutics AG | Sortase f and its use in methods for conjugation |
JP2022512860A (en) | 2018-11-06 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and Pharmaceutical Compositions for the Treatment of Acute Myeloid Leukemia by Eradication of Leukemia Stem Cells |
MX2021005808A (en) | 2018-11-20 | 2021-07-02 | Univ Cornell | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer. |
AU2019387377A1 (en) | 2018-11-30 | 2021-06-17 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD38 immunotherapy |
KR20210100668A (en) | 2018-12-06 | 2021-08-17 | 제넨테크, 인크. | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugate, an alkylating agent and an anti-CD20 antibody |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2020120786A1 (en) | 2018-12-14 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
WO2020127411A1 (en) | 2018-12-19 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d |
WO2020127968A1 (en) | 2018-12-20 | 2020-06-25 | Marino Stephen F | Protein-drug conjugate comprising a monomeric form of proteinase 3 |
GB201820864D0 (en) * | 2018-12-20 | 2019-02-06 | J A Kemp | Antibody-drug conjugates |
CA3123619A1 (en) | 2018-12-21 | 2020-06-25 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibodies and uses thereof |
KR20210124308A (en) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | Anti-GAL3 antibodies and uses thereof |
CA3128097A1 (en) | 2019-02-05 | 2020-08-13 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
TWI756633B (en) | 2019-02-15 | 2022-03-01 | 大陸商上海藥明生物技術有限公司 | Antibody-drug conjugates with improved homogeneity, pharmaceutical compositions thereof, uses and methods of preparation |
CN109652384B (en) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | Method for culturing hepatitis E virus in vitro |
US11242407B2 (en) | 2019-02-26 | 2022-02-08 | Inspirna, Inc. | High-affinity anti-MERTK antibodies and uses thereof |
KR20210134725A (en) | 2019-03-01 | 2021-11-10 | 젠코어 인코포레이티드 | Heterodimeric Antibodies that Bind to ENPP3 and CD3 |
US20220168344A1 (en) | 2019-03-06 | 2022-06-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
KR20210154158A (en) | 2019-03-20 | 2021-12-20 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Claudin-6 Antibody and Drug Conjugates |
WO2020213084A1 (en) | 2019-04-17 | 2020-10-22 | Keio University | Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
WO2020225323A1 (en) | 2019-05-06 | 2020-11-12 | Seekyo | New therapeutic vectors and prodrugs for treating cancers |
CA3138045C (en) | 2019-05-14 | 2024-02-20 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
CR20210576A (en) | 2019-05-21 | 2021-12-15 | Novartis Ag | Cd19 binding molecules and uses thereof |
JP2022535005A (en) | 2019-05-30 | 2022-08-04 | レンティジェン・テクノロジー・インコーポレイテッド | Compositions and methods for treating cancer with anti-BCMA immunotherapy |
TW202112354A (en) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | Masked antibody formulations |
US20220306727A1 (en) | 2019-06-05 | 2022-09-29 | Seagen Inc. | Methods of Purifying Masked Antibodies |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
EP3983363B1 (en) | 2019-06-17 | 2024-04-10 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for high click release speed and yield |
EA202290208A1 (en) | 2019-07-02 | 2022-03-25 | Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз | MONOCLONAL ANTIBODIES THAT BIND EGFRvIII AND THEIR APPLICATIONS |
AU2020318975A1 (en) | 2019-07-22 | 2022-03-17 | Seagen Inc. | Humanized anti-LIV1 antibodies for the treatment of cancer |
KR20220041915A (en) | 2019-08-06 | 2022-04-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Biopharmaceutical compositions and related methods |
WO2021026409A1 (en) | 2019-08-08 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
KR20220061977A (en) | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Methods and compositions for promoting and enhancing T cell mediated immune response through ADCC targeting of CD39 expressing cells |
EP4025253B1 (en) | 2019-09-05 | 2024-03-20 | Pharma Mar, S.A. | Drug antibody conjugates |
CN112125915A (en) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | Camptothecin derivative and conjugate thereof |
WO2021055865A1 (en) | 2019-09-19 | 2021-03-25 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
AU2020351751A1 (en) | 2019-09-25 | 2022-04-21 | Seagen Inc. | Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers |
US20220362397A1 (en) | 2019-09-26 | 2022-11-17 | Nof Corporation | Heterobifunctional monodispersed polyethylene glycol having peptide linker |
WO2021064184A1 (en) | 2019-10-04 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
US20230165967A1 (en) | 2019-10-04 | 2023-06-01 | TAE Life Sciences | Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for use in Treating Cancer, Immunological Disorders, and Methods Thereof |
MX2022003517A (en) | 2019-10-04 | 2022-04-25 | Seagen Inc | Anti-pd-l1 antibodies and antibody-drug conjugates. |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
AU2020365836A1 (en) | 2019-10-18 | 2022-04-28 | F. Hoffmann-La Roche Ag | Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
CN114786730A (en) | 2019-11-05 | 2022-07-22 | 再生元制药公司 | N-terminal scFv multispecific binding molecules |
TW202131954A (en) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
AU2020380732A1 (en) | 2019-11-07 | 2022-06-02 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
WO2022106869A1 (en) | 2019-11-22 | 2022-05-27 | Medimmune Limited | Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
CN115052663A (en) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | ALK5 inhibitor conjugates and uses thereof |
TW202140078A (en) | 2020-01-22 | 2021-11-01 | 大陸商上海森輝醫藥有限公司 | Drug conjugates of eribulin derivatives, preparation method and medical use thereof |
WO2021178597A1 (en) | 2020-03-03 | 2021-09-10 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
CN115315446A (en) | 2020-03-06 | 2022-11-08 | Go医疗股份有限公司 | anti-sugar-CD 44 antibodies and uses thereof |
WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
TW202144013A (en) | 2020-03-25 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pharmaceutical composition comprising an antibody drug conjugate, and use thereof |
CA3175048A1 (en) | 2020-03-25 | 2021-09-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for antibody medicament conjugate |
EP4126241A1 (en) | 2020-03-27 | 2023-02-08 | Novartis AG | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
AU2021241682A1 (en) | 2020-03-27 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
US20230173093A1 (en) | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
MX2022013298A (en) | 2020-04-21 | 2022-11-30 | Pharma Mar Sa | Drug antibody conjugates. |
MX2022013198A (en) | 2020-04-24 | 2022-11-14 | Genentech Inc | Methods of using anti-cd79b immunoconjugates. |
WO2021221927A1 (en) | 2020-04-27 | 2021-11-04 | Parsons Corporation | Narrowband iq signal obfuscation |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
US20230302050A1 (en) | 2020-05-20 | 2023-09-28 | Institut Curie | Single Domain Antibodies and Their Use in Cancer Therapies |
JP2023528632A (en) | 2020-06-05 | 2023-07-05 | テッサ・セラピューティクス・リミテッド | Treatment of CD30 positive cancer |
EP4163294A1 (en) | 2020-06-09 | 2023-04-12 | Ajinomoto Co., Inc. | Modified ferritin and method for producing same |
AU2021296423A1 (en) | 2020-06-22 | 2023-02-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy |
KR20230028492A (en) | 2020-06-29 | 2023-02-28 | 젠맵 에이/에스 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
EP4189071A1 (en) | 2020-08-03 | 2023-06-07 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy |
CN116568337A (en) | 2020-08-04 | 2023-08-08 | 思进股份有限公司 | anti-CD 228 antibodies and antibody-drug conjugates |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | Anti-cd28 compositions |
CN112062855A (en) | 2020-08-26 | 2020-12-11 | 康诺亚生物医药科技(成都)有限公司 | Development and application of medicinal therapeutic agent containing adapter |
EP4213943A1 (en) | 2020-09-15 | 2023-07-26 | The University Of Montana | Compositions and methods targeting filamentous bacteriophage |
EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
WO2022067348A1 (en) | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
EP4229090A1 (en) | 2020-10-16 | 2023-08-23 | Université d'Aix-Marseille | Anti-gpc4 single domain antibodies |
CN116801898A (en) | 2020-11-05 | 2023-09-22 | 莱蒂恩技术公司 | Compositions and methods for treating cancer with anti-CD 19/CD22 immunotherapy |
WO2022098972A1 (en) | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
CN114524878A (en) | 2020-11-23 | 2022-05-24 | 康诺亚生物医药科技(成都)有限公司 | Bispecific antibody and application thereof |
CN114573703A (en) | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技(成都)有限公司 | Development and application of T cell adaptor therapeutic agent |
CN114573702A (en) | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技(成都)有限公司 | Development and application of novel tumor adaptor treatment drug |
EP4261225A1 (en) | 2020-12-10 | 2023-10-18 | Eutilex Co., Ltd. | Anti-pd-1 antibody and uses thereof |
KR20230124684A (en) | 2020-12-23 | 2023-08-25 | 루드비히-막시밀리안스-우니버지테트 뮌헨 | Improved CD30 Targeting Antibody Drug Conjugates and Uses Thereof |
CN114685657A (en) | 2020-12-31 | 2022-07-01 | 康诺亚生物医药科技(成都)有限公司 | Development and application of function-enhanced antibody blocking agent |
CN114716548A (en) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | anti-FGFR 3 antibodies and uses thereof |
WO2022152862A1 (en) | 2021-01-14 | 2022-07-21 | Institut Curie | Her2 single domain antibodies variants and cars thereof |
WO2022154127A1 (en) | 2021-01-18 | 2022-07-21 | 味の素株式会社 | Compound or salt thereof, and antibody obtained therefrom |
EP4279500A1 (en) | 2021-01-18 | 2023-11-22 | Ajinomoto Co., Inc. | Compound or salt thereof, and antibody produced using same |
AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
EP4284919A1 (en) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
WO2022180242A2 (en) | 2021-02-26 | 2022-09-01 | Forschungsverbund Berlin E.V. | Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives |
JP2024512324A (en) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | Anti-glycoCD44 antibodies and their uses |
KR20230156079A (en) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Heterodimeric antibody binding to CD3 and CLDN6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CN116964076A (en) | 2021-03-11 | 2023-10-27 | 味之素株式会社 | Compounds or salts thereof, and antibodies derived therefrom |
WO2022196675A1 (en) | 2021-03-16 | 2022-09-22 | 味の素株式会社 | Complex or salt thereof, and method for manufacturing same |
AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
IL305886A (en) | 2021-03-18 | 2023-11-01 | Seagen Inc | Selective drug release from internalized conjugates of biologically active compounds |
WO2022200303A1 (en) | 2021-03-23 | 2022-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of t cell-lymphomas |
EP4316527A1 (en) | 2021-03-31 | 2024-02-07 | MicroBiopharm Japan Co., Ltd. | Method for manufacturing antibody-drug conjugate and enzyme used for same |
WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
AU2022262606A1 (en) | 2021-04-21 | 2023-11-09 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
EP4326335A1 (en) | 2021-04-23 | 2024-02-28 | Forschungsverbund Berlin E.V. | Thiol-conjugation with unsaturated phosphorus(v) compounds |
CA3218235A1 (en) | 2021-04-27 | 2022-11-03 | Baylor College Of Medicine | Virus-specific immune cells expressing chimeric antigen receptors |
US11931420B2 (en) | 2021-04-30 | 2024-03-19 | Celgene Corporation | Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
TW202310876A (en) | 2021-05-12 | 2023-03-16 | 美商建南德克公司 | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
KR20240013732A (en) | 2021-05-26 | 2024-01-30 | 옥스포드 바이오테라퓨틱스 리미티드 | Pharmaceutical combination comprising an anti-CD205 antibody and an immune checkpoint inhibitor |
TW202320857A (en) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | Linkers, drug linkers and conjugates thereof and methods of using the same |
WO2023288236A1 (en) | 2021-07-14 | 2023-01-19 | Seagen Inc. | Antibody masking domains |
IL310392A (en) | 2021-08-03 | 2024-03-01 | Glaxosmithkline Ip Dev Ltd | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
US20230099756A1 (en) | 2021-08-07 | 2023-03-30 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
WO2023031445A2 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
FR3126982B1 (en) | 2021-09-14 | 2023-09-15 | Centre Nat Rech Scient | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE |
CA3231944A1 (en) | 2021-09-16 | 2023-03-23 | Carole GUILLONNEAU | Anti-human cd45rc binding domains and uses thereof |
CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
WO2023054706A1 (en) | 2021-09-30 | 2023-04-06 | 味の素株式会社 | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof |
WO2023072953A1 (en) | 2021-10-26 | 2023-05-04 | Tessa Therapeutics Ltd. | Cell lines for producing a retroviral vector encoding a car |
US20230158154A1 (en) | 2021-11-09 | 2023-05-25 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a camptothecin moiety |
US20230330258A1 (en) | 2021-11-09 | 2023-10-19 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a drug moiety |
WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104910A1 (en) | 2021-12-08 | 2023-06-15 | Tessa Therapeutics Ltd. | Treatment of lymphoma |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
US20230338424A1 (en) | 2022-03-02 | 2023-10-26 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy |
WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024013724A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody-drug conjugates |
WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
WO2024026107A2 (en) | 2022-07-28 | 2024-02-01 | Lentigen Technology, Inc. | Chimeric antigen receptor therapies for treating solid tumors |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
WO2024041543A1 (en) * | 2022-08-22 | 2024-02-29 | Suzhou Bioreinno Biotechnology Limited Company | A method of preparing an antibody with thiol group site-specific modifications and use of tcep |
WO2024041544A1 (en) * | 2022-08-22 | 2024-02-29 | Suzhou Bioreinno Biotechnology Limited Company | A method of preparing an antibody with site-specific modifications |
US20240075142A1 (en) | 2022-08-26 | 2024-03-07 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy |
US20240116945A1 (en) | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
WO2024064714A2 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Antibodies that bind cd228 |
CN116239513B (en) * | 2023-05-05 | 2023-08-18 | 天津凯莱英制药有限公司 | Preparation method of MMAE key intermediate, preparation method of MMAE and antibody coupling drug |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3445518A (en) | 1966-05-06 | 1969-05-20 | Warner Lambert Pharmaceutical | P-acylphenylethylamines |
US4414205A (en) | 1981-08-28 | 1983-11-08 | University Patents, Inc. | Cell growth inhibitory substances |
CA1213229A (en) | 1982-04-12 | 1986-10-28 | Gary S. David | Antibodies having dual specificities, their preparation and uses therefor |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US4764368A (en) * | 1984-08-29 | 1988-08-16 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
CA1282069C (en) | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
JPH01202700A (en) | 1988-02-09 | 1989-08-15 | Mitsubishi Electric Corp | X-ray mirror and its manufacturing method |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
US4943628A (en) | 1988-06-13 | 1990-07-24 | Ortho Pharmaceutical Corporation | HIV peptide-inducted T cell stimulation |
SG52662A1 (en) | 1988-08-12 | 1998-09-28 | Astra Ab | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
US5767236A (en) | 1990-05-09 | 1998-06-16 | Biomeasure, Inc. | Linear therapeutic peptides |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE69233254T2 (en) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
JP2618597B2 (en) | 1991-08-09 | 1997-06-11 | 帝国臓器製薬株式会社 | New tetrapeptide derivatives |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
EP0659759B1 (en) | 1992-09-09 | 1999-12-08 | Nippon Kayaku Kabushiki Kaisha | Novel physiologically active substance nk175203, process for producing the same, and pharmaceutical use thereof |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
JPH06234790A (en) | 1993-02-09 | 1994-08-23 | Teikoku Hormone Mfg Co Ltd | New tetrapeptide derivative |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
FR2710536B1 (en) | 1993-09-29 | 1995-12-22 | Transgene Sa | Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response. |
US5767237A (en) | 1993-10-01 | 1998-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Peptide derivatives |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
EP0805871B2 (en) | 1995-01-18 | 2006-02-22 | Roche Diagnostics GmbH | Anti-cd30 antibodies preventing proteolytic cleavage and release of membrane-bound cd30 antigen |
EP0831100B1 (en) | 1995-04-21 | 2000-10-11 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivatives |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
JPH0977791A (en) | 1995-09-08 | 1997-03-25 | Nippon Kayaku Co Ltd | Peptide derivative and its use |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
US5741892A (en) | 1996-07-30 | 1998-04-21 | Basf Aktiengesellschaft | Pentapeptides as antitumor agents |
WO1998013059A1 (en) | 1996-09-27 | 1998-04-02 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US5965537A (en) | 1997-03-10 | 1999-10-12 | Basf Aktiengesellschaft | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
US6143721A (en) | 1997-07-18 | 2000-11-07 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
US6620911B1 (en) | 1998-01-09 | 2003-09-16 | Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University | Anti-cryptococcal peptides |
US6162930A (en) | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
JP2000009062A (en) | 1998-06-18 | 2000-01-11 | Sanden Corp | Scroll type compressor |
US5985837A (en) | 1998-07-08 | 1999-11-16 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
US7425541B2 (en) * | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
US7115261B1 (en) * | 1999-02-12 | 2006-10-03 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
EP1185559A2 (en) | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
BR0013201A (en) * | 1999-07-12 | 2002-04-30 | Genentech Inc | Method of blocking an immune response to an external antigen in mammals through the use of an antagonist that binds to cd20, method of treating mammals, method of treating a disease of graft versus host or host versus graft in mammals, method of numbness of mammals awaiting transplantation and industrialized article |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
BR0110610A (en) * | 2000-04-11 | 2003-04-29 | Genentech Inc | Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
US6737409B2 (en) | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
US20040235068A1 (en) | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US20050238650A1 (en) | 2002-04-17 | 2005-10-27 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
MXPA04008419A (en) | 2002-03-01 | 2004-11-26 | Univ Tulane | Conjugates of therapeutic or cytotoxic agents and biologically active peptides. |
SI1572087T1 (en) | 2002-03-08 | 2008-10-31 | Pdl Biopharma Inc | Antibodies against cancer antigen tmeff2 and uses thereof |
AU2003228336B2 (en) | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
PT1545613E (en) | 2002-07-31 | 2011-09-27 | Seattle Genetics Inc | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
WO2004016801A2 (en) | 2002-08-16 | 2004-02-26 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
JP4898120B2 (en) | 2002-12-20 | 2012-03-14 | アボット バイオセラピューティクス コーポレイション | Antibodies against GPR64 and methods of use thereof |
EP2289559B1 (en) | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
AU2004224390A1 (en) | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
BR122018071808B8 (en) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
US7399469B2 (en) | 2004-03-26 | 2008-07-15 | Pdl Biopharma, Inc. | Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer |
US7442332B2 (en) * | 2004-05-04 | 2008-10-28 | Clopay Plastic Products Company, Inc. | Method and apparatus for uniformly stretching thermoplastic film and products produced thereby |
US7312343B2 (en) | 2004-06-02 | 2007-12-25 | Hoffmann-La Roche Inc. | Synthesis of α-amino-β-alkoxy-carboxylic acid esters |
EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2006041641A2 (en) | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Therapeutic agents with decreased toxicity |
DK1827492T3 (en) | 2004-11-30 | 2010-11-22 | Curagen Corp | Antibodies targeting GPNMB and uses thereof |
EP1828117A1 (en) | 2004-12-13 | 2007-09-05 | F. Hoffmann-Roche AG | Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives |
AU2006210837B2 (en) | 2005-01-31 | 2012-07-12 | Genentech, Inc. | Anti-EphB2 antibodies and methods using same |
WO2006104978A2 (en) | 2005-03-25 | 2006-10-05 | Curagen Corporation | Antibodies against the tenascin major antigens |
CA2612762C (en) | 2005-06-20 | 2013-12-10 | Psma Development Company, Llc | Psma antibody-drug conjugates |
US20090304721A1 (en) * | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
EP1957115B8 (en) | 2005-11-10 | 2014-03-05 | Celldex Therapeutics, Inc. | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
WO2007062138A2 (en) | 2005-11-23 | 2007-05-31 | Applera Corporation | Methods and compositions for treating diseases targeting human prominin-1(cd133) |
DOP2006000277A (en) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | ANTI MN ANTIBODIES AND METHODS FOR USE |
AR059900A1 (en) | 2006-03-17 | 2008-05-07 | Genentech Inc | ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS |
-
2003
- 2003-07-31 PT PT03772186T patent/PT1545613E/en unknown
- 2003-07-31 EP EP20110165204 patent/EP2353611B1/en not_active Expired - Lifetime
- 2003-07-31 US US10/522,911 patent/US7659241B2/en active Active
- 2003-07-31 PT PT111652103T patent/PT2357006E/en unknown
- 2003-07-31 CA CA2802205A patent/CA2802205C/en not_active Expired - Lifetime
- 2003-07-31 SI SI200332457T patent/SI2357006T1/en unknown
- 2003-07-31 DK DK11165210.3T patent/DK2357006T3/en active
- 2003-07-31 ES ES03772186T patent/ES2369542T3/en not_active Expired - Lifetime
- 2003-07-31 SI SI200332051T patent/SI1545613T1/en unknown
- 2003-07-31 CA CA2494105A patent/CA2494105C/en not_active Expired - Lifetime
- 2003-07-31 HU HUE11165210A patent/HUE027549T2/en unknown
- 2003-07-31 DK DK03772186.7T patent/DK1545613T3/en active
- 2003-07-31 AU AU2003263964A patent/AU2003263964C1/en active Active
- 2003-07-31 JP JP2004524294A patent/JP4741838B2/en not_active Expired - Lifetime
- 2003-07-31 EP EP11165210.3A patent/EP2357006B1/en not_active Expired - Lifetime
- 2003-07-31 ES ES11165210.3T patent/ES2556641T3/en not_active Expired - Lifetime
- 2003-07-31 ES ES11165204.6T patent/ES2544527T3/en not_active Expired - Lifetime
- 2003-07-31 WO PCT/US2003/024209 patent/WO2004010957A2/en active Application Filing
- 2003-07-31 EP EP03772186A patent/EP1545613B9/en not_active Expired - Lifetime
- 2003-07-31 AT AT03772186T patent/ATE516818T1/en active
-
2008
- 2008-01-18 US US12/016,978 patent/US20080213289A1/en not_active Abandoned
-
2009
- 2009-03-20 US US12/408,646 patent/US7829531B2/en not_active Expired - Lifetime
- 2009-11-18 US US12/621,406 patent/US7851437B2/en not_active Expired - Lifetime
-
2010
- 2010-04-13 AU AU2010201459A patent/AU2010201459B2/en not_active Expired
- 2010-09-10 US US12/880,028 patent/US8906376B2/en active Active
-
2011
- 2011-09-07 CY CY20111100855T patent/CY1111894T1/en unknown
- 2011-09-12 HK HK11109608.2A patent/HK1157180A1/en not_active IP Right Cessation
-
2012
- 2012-10-31 FR FR12C0066C patent/FR12C0066I2/en active Active
- 2012-10-31 BE BE2012C047C patent/BE2012C047I2/fr unknown
-
2013
- 2013-01-10 CY CY2013004C patent/CY2013004I2/en unknown
- 2013-01-16 LU LU92133C patent/LU92133I2/en unknown
- 2013-01-18 HU HUS1300002C patent/HUS1300002I1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11944689B2 (en) | 2016-08-09 | 2024-04-02 | Seagen Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2494105A1 (en) | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | |
AU2021201636B2 (en) | Self-stabilizing linker conjugates | |
JP2006500333A5 (en) | ||
ES2523915T5 (en) | Variant Target Binding Agents and Uses Thereof | |
JP2023018157A (en) | Hydrophilic antibody-drug conjugates | |
ES2457538T3 (en) | Anti-CD70-drug antibody conjugates and their use for the treatment of cannula and immune disorders | |
ES2456325T3 (en) | Monomethylvaline compounds capable of conjugation with ligands | |
ES2715776T3 (en) | Auristatins that have an aminobenzoic acid unit at the N-terminus | |
HRP20161345T1 (en) | Cd19 binding agents and uses thereof | |
CA2775350A1 (en) | Dr5 ligand drug conjugates | |
CA2556752A1 (en) | Heterocyclic self-immolative linkers and conjugates | |
AU2002363939A1 (en) | Treatment of immunological disorders using anti-cd30 antibodies | |
JP2008519863A5 (en) | ||
JP2015524796A5 (en) | Conjugates of cytotoxic agents and cell-bound receptors | |
KR20150003836A (en) | Dr5 ligand drug conjugates | |
WO2014134486A2 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
US20080279768A1 (en) | Bifunctional Metal Chelating Conjugates | |
CA2381123A1 (en) | Actinium-225 complexes and conjugates for radioimmunotherapy | |
JP2005047821A (en) | Diagnostic or therapeutic medicine using cyclopentadienyl carbonyl group-containing radiactive compound | |
RU2002106728A (en) | ACTINIA-225 COMPLEXES AND CONJUGATES FOR RADIOIMMUNOTHERAPY | |
KR0132614B1 (en) | Functionalized polyamine chelants and rhodium complexes thereof for conjugation to antibodies | |
EA040940B1 (en) | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | |
NZ722252B2 (en) | Hydrophilic antibody-drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20230731 |